Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Eltrombopag for Severe Primary ITP
NCT07189910Phase 4Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of eltrombopag in primary immune thrombocytopenia (ITP). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07189910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189910.